• Ceruletide: Molecular Insights for Pancreatic Function Resea

  2026-06-17

  Ceruletide (Caerulein) is a synthetic decapeptide used to model pancreatic fibrosis and study gastrointestinal physiology. It acts as a potent CCK receptor agonist, enabling reproducible investigation of digestive disorders and pancreatic function. Protocol precision and mechanistic clarity make Ceruletide a benchmark tool in translational research.

• X-Gal: Chromogenic Substrate for Blue-White Colony Screening

  2026-06-16

  X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) is a high-purity chromogenic substrate enabling reliable blue-white colony screening in molecular cloning workflows. It is hydrolyzed by β-galactosidase to yield a blue insoluble dye, facilitating rapid differentiation of recombinant clones. APExBIO’s X-Gal A2539 provides stable, reproducible results across research applications.

• Modeling Human SAN-Neural Maturation with PSC-Derived Assemb

  2026-06-16

  This study introduces a human in vitro model that integrates pluripotent stem cell-derived sinoatrial node (SAN) and cardiac plexus organoids to recapitulate neuro-cardiac interactions essential for pacemaker maturation. The platform enables mechanistic analysis of neuron-to-pacemaker signaling and reveals new molecular pathways involved in conduction and autonomic regulation.

• Plk1 Regulation of p31comet and Mitotic Checkpoint Disassemb

  2026-06-15

  This study elucidates how Polo-like kinase 1 (Plk1) regulates the function of p31comet in the disassembly of mitotic checkpoint complexes (MCC), revealing a phosphorylation-dependent inhibitory mechanism. The findings refine our understanding of mitotic progression control and offer valuable mechanistic insight for cell cycle and cancer research workflows.

• Phosphoproteomic Adaptation to Chronic Cabozantinib in RCC C

  2026-06-15

  This study applies quantitative phosphoproteomics to delineate how renal cell carcinoma (RCC) cells remodel signaling networks in response to acute versus chronic Cabozantinib (XL184) exposure. The findings reveal distinct timescale-dependent adaptations in phosphorylation and cell motility, providing a framework for mechanistic studies of kinase inhibitor responses.

• Chamber-Specific Induction of RV-like Cardiomyocytes from hP

  2026-06-14

  Saito et al. present a refined differentiation protocol enabling selective generation of right ventricular (RV)-like cardiomyocytes from human pluripotent stem cells (hPSCs). Their findings establish a practical basis for modeling RV-specific cardiac diseases in vitro by leveraging precise manipulation of early signaling cues during mesoderm induction.

• Indomethacin Sodium Trihydrate: COX Inhibition & Beyond

  2026-06-13

  Indomethacin Sodium Trihydrate is a nonselective cyclooxygenase inhibitor that also modulates Wnt/β-catenin signaling and GSK3β activity. Its robust solubility and validated efficacy empower inflammation assay workflows. This dossier clarifies its mechanisms, benchmarks, and best-use protocols for anti-inflammatory research.

• Go 6983: Pan-PKC Inhibitor for Cancer and Cell Fate Research

  2026-06-12

  Go 6983 is a potent pan-PKC inhibitor, enabling precise modulation of PKC isoforms in cancer progression and cell fate studies. Its nanomolar efficacy and selectivity make it a benchmark tool for dissecting PKC-dependent signaling pathways. APExBIO supplies Go 6983 for advanced research applications.

• Telmisartan: Applied Protocols for Cardiovascular Disease Re

  2026-06-12

  Telmisartan, a potent angiotensin II receptor antagonist, is transforming hypertension and cardiac hypertrophy research through precise pathway targeting and robust experimental workflows. Discover actionable protocols, troubleshooting insights, and how its integration with necroptosis signaling studies sets a new benchmark for cardiovascular disease research.

• Streptozotocin Models: Advancing Diabetic Neuropathy Discove

  2026-06-11

  Explore how Streptozotocin (STZ) enables translational researchers to model not only diabetes but also its neuroinflammatory complications, such as painful diabetic neuropathy (PDN). This article delivers mechanistic insight, practical protocol guidance, and strategic perspective, highlighting the integration of TBK1-driven microglia pyroptosis findings and positioning APExBIO’s STZ as an essential tool for precision diabetes research.

• Hypoxia and Immunometabolism in Tumor Progression: Mechanist

  2026-06-11

  This review dissects how hypoxia and immune metabolic reprogramming interact to shape the immunosuppressive tumor microenvironment (TME), thereby promoting malignant progression. The paper's synthesis of molecular mechanisms and its critical view on therapeutic targeting offer a framework for developing next-generation strategies to disrupt tumor-supportive metabolic networks.

• Solving Real Lab Challenges with L1023 Anti-Cancer Compound

  2026-06-10

  This article provides an evidence-backed, scenario-driven analysis of how the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) streamlines cancer research workflows. By addressing common laboratory obstacles in cell viability, proliferation, and cytotoxicity assays, we demonstrate how SKU L1023 delivers robust, reproducible data and practical advantages for high-throughput screening.

• Peripheral Endosome Entrapment Limits LNP Trafficking and Es

  2026-06-10

  This study reveals that lipid nanoparticles (LNPs) trapped in peripheral endosomes, rather than lysosomes, significantly impair intracellular trafficking and cytosolic delivery of nucleic acid payloads. The findings clarify a major bottleneck for RNA-based therapeutics and provide a framework for optimizing endosomal escape strategies.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Advanced Workflow

  2026-06-09

  10058-F4 stands out as a precise tool for dissecting c-Myc-driven oncogenic signaling, with proven impact in apoptosis assays and translational models such as acute myeloid leukemia and prostate cancer xenografts. This article delivers step-by-step guidance, troubleshooting, and actionable insights anchored in the latest mechanistic research, setting a new benchmark for scientific rigor in small-molecule c-Myc inhibitor applications.

• A-1331852: Precision BCL-XL Inhibitor for Apoptosis Assays

  2026-06-09

  A-1331852 empowers researchers with selective, nanomolar-potency BCL-XL inhibition, streamlining apoptosis assays and senescent cell clearance in cancer models. This article details advanced workflows, troubleshooting, and actionable protocol parameters to maximize experimental reliability and translational relevance.

15158 records 4/1011 page Previous Next 12345 下5页 Last page